Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × romiplostim × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 7 Lymphoid 5 Plasma cell 3 Thoracic 2 Gynecologic 2 Sarcoma 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Gastrointestinal 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Interventions

pembrolizumab 276 Nivolumab 244 Ipilimumab 217 Cyclophosphamide 167 aldesleukin 126 Interleukin-2 91 fludarabine phosphate 87 fludarabine 71 trametinib 67 Radiotherapy 66 Dacarbazine 66 Temozolomide 65 Vemurafenib 59 dabrafenib 58 Biopsy 54 Radiosurgery 46 Bevacizumab 45 sargramostim 43 Imiquimod 43 Magnetic Resonance Spectroscopy 42 Aminolevulinic Acid 40 Peripheral Blood Stem Cell Transplantation 39 Cisplatin 39 Paclitaxel 38 Carboplatin 36 3-ingenyl angelate 36 incomplete Freund's adjuvant 35 Specimen Handling 35 Filgrastim 35 cemiplimab 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04427306 2023-09-15

Neoadjuvant T-VEC in High Risk Early Melanoma

University of California, Davis

Phase 2 Suspended

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡